Diagnosis and management of autoimmune hepatitis

Clinics in Liver Disease

Volumn 19, Issue 1, 2015, Pages 57-79

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune; Diagnosis; Hepatitis; Salvage therapies; Steroids; Suboptimal responses

Indexed keywords

ACTIN ANTIBODY; ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CYCLOSPORIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; LIVER ANTIGEN; LIVER KIDNEY MICROSOME TYPE 1 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BILE DUCT INJURY; BONE MARROW DEPRESSION; CHOLANGIOGRAPHY; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CYTOPENIA; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GRAFT DYSFUNCTION; GRAVES DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MENTAL INSTABILITY; MONOTHERAPY; NAUSEA; OBESITY; OFF LABEL DRUG USE; PANCREATITIS; RASH; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SALVAGE THERAPY; SCORING SYSTEM; SJOEGREN SYNDROME; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; VACCINATION; VERTEBRA COMPRESSION; VITAMIN SUPPLEMENTATION; VOMITING; BLOOD; DRUG COMBINATION; HEPATITIS, AUTOIMMUNE; RECURRENT DISEASE; RETREATMENT; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECURRENCE; RETREATMENT; TREATMENT FAILURE;

EID: 84927601091     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.09.004     Document Type: Review

References (100)

1. Manns M.P., Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
2. Gleeson D., Heneghan M.A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011, 60:1611-1629.
3. Gregorio G.V., Portmann B., Reid F., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
4. Czaja A.J., Carpenter H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006, 43:532-538.
5. Czaja A.J. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 2013, 7:365-385.
6. Kogan J., Safadi R., Ashur Y., et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. JClin Gastroenterol 2002, 35:75-81.
7. Feld J.J., Dinh H., Arenovich T., et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005, 42:53-62.
8. Kessler W.R., Cummings O.W., Eckert G., et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004, 2:625-631.
9. Burgart L.J., Batts K.P., Ludwig J., et al. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995, 19:699-708.
10. Davis G.L., Czaja A.J., Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984, 87:1222-1227.
11. Czaja A.J., Rakela J., Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988, 95:448-453.
12. Ludwig J., Czaja A.J., Dickson E.R., et al. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 1984, 4:105-116.
13. Czaja A.J. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012, 57:2248-2266.
14. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
15. Werner M., Prytz H., Ohlsson B., et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008, 43:1232-1240.
16. Stravitz R.T., Lefkowitch J.H., Fontana R.J., et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011, 53:517-526.
17. Czaja A.J. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013, 58:897-914.
18. Czaja A.J. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci 2011, 56:3421-3438.
19. Czaja A.J. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol 2007, 1:129-143.
20. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72.
21. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. JHepatol 1999, 31:929-938.
22. Czaja A.J., Carpenter H.A. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 1996, 41:305-314.
23. Kaukinen K., Halme L., Collin P., et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002, 122:881-888.
24. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
25. Czaja A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48:1540-1548.
26. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. JHepatol 2011, 54:374-385.
27. Czaja A.J. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci 2011, 56:545-554.
28. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
29. Czaja A.J., Manns M.P. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995, 90:1206-1211.
30. Czaja A.J., Norman G.L. Autoantibodies in the diagnosis and management of liver disease. JClin Gastroenterol 2003, 37:315-329.
31. Czaja A.J., Shums Z., Norman G.L. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004, 37:195-201.
32. Bansi D., Chapman R., Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. JHepatol 1996, 24:581-586.
33. Baeres M., Herkel J., Czaja A.J., et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002, 51:259-264.
34. Eyraud V., Chazouilleres O., Ballot E., et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009, 29:857-864.
35. Montano-Loza A.J., Shums Z., Norman G.L., et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012, 32:85-92.
36. Czaja A.J., Donaldson P.T., Lohse A.W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002, 97:413-419.
37. Ma Y., Okamoto M., Thomas M.G., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
38. Frenzel C., Herkel J., Luth S., et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006, 101:2731-2736.
39. Gueguen P., Dalekos G., Nousbaum J.B., et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. JClin Immunol 2006, 26:495-505.
40. Volta U., De Franceschi L., Molinaro N., et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998, 43:2190-2195.
41. Czaja A.J., Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993, 105:1824-1832.
42. Czaja A.J., Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001, 34:659-665.
43. Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011, 54:931-939.
44. Carpenter H.A., Czaja A.J. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002, 6:685-705.
45. Czaja A.J., Carpenter H.A. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007, 5:898-907.
46. Bjornsson E., Talwalkar J., Treeprasertsuk S., et al. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011, 9:57-63.
47. Miyake Y., Iwasaki Y., Terada R., et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007, 37:801-805.
48. Czaja A.J., Muratori P., Muratori L., et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004, 24:322-329.
49. Czaja A.J. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008, 25:219-239.
50. Czaja A.J. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014, 12:1430-1438.
51. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.
52. Lewin M., Vilgrain V., Ozenne V., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009, 50:528-537.
53. Czaja A.J. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012, 57:1996-2010.
54. Czaja A.J. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013, 38:343-364.
55. Czaja A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009, 29:816-823.
56. Summerskill W.H., Korman M.G., Ammon H.V., et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975, 16:876-883.
57. Manns M.P., Woynarowski M., Kreisel W., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
58. Czaja A.J. Drug choices in autoimmune hepatitis: part A-steroids. Expert Rev Gastroenterol Hepatol 2012, 6:603-615.
59. Geier A., Gartung C., Dietrich C.G., et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003, 9:2681-2685.
60. Efe C., Ozaslan E., Kav T., et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012, 11:330-334.
61. Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
62. Zachou K., Gatselis N., Papadamou G., et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. JHepatol 2011, 55:636-646.
63. Worns M.A., Teufel A., Kanzler S., et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008, 103:138-146.
64. Czaja A.J. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008, 7:319-333.
65. Bajaj J.S., Saeian K., Varma R.R., et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005, 100:1121-1125.
66. Czaja A.J. Drug choices in autoimmune hepatitis: part B-nonsteroids. Expert Rev Gastroenterol Hepatol 2012, 6:617-635.
67. Ngu J.H., Gearry R.B., Frampton C.M., et al. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012, 55:522-529.
68. Francella A., Dyan A., Bodian C., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9-17.
69. Casanova M.J., Chaparro M., Domenech E., et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013, 108:433-440.
70. Langley P.G., Underhill J., Tredger J.M., et al. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. JHepatol 2002, 37:441-447.
71. Czaja A.J., Carpenter H.A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006, 51:968-975.
72. Heneghan M.A., Allan M.L., Bornstein J.D., et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. JHepatol 2006, 45:584-591.
73. Ferucci E.D., Hurlburt K.J., Mayo M.J., et al. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Can J Gastroenterol 2011, 25:21-27.
74. Stocco G., Londero M., Campanozzi A., et al. Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. JCrohns Colitis 2010, 4:599-602.
75. Soloway R.D., Summerskill W.H., Baggenstoss A.H., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63:820-833.
76. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. JHepatol 2004, 40:646-652.
77. Czaja A.J. Review article: prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014, 39:385-406.
78. Roberts S.K., Therneau T.M., Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110:848-857.
79. Delgado J.S., Vodonos A., Malnick S., et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. JDig Dis 2013, 14:611-618.
80. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007, 46:1138-1145.
81. Czaja A.J., Davis G.L., Ludwig J., et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984, 4:622-627.
82. Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. JHepatol 2009, 51:161-167.
83. Kanzler S., Gerken G., Lohr H., et al. Duration of immunosuppressive therapy in autoimmune hepatitis. JHepatol 2001, 34:354-355.
84. Czaja A.J., Carpenter H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003, 23:116-123.
85. Czaja A.J., Wolf A.M., Baggenstoss A.H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981, 80:687-692.
86. Czaja A.J., Menon K.V., Carpenter H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002, 35:890-897.
87. Czaja A.J. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010, 55:1761-1769.
88. Seo S., Toutounjian R., Conrad A., et al. Favorable outcomes of autoimmune hepatitis in a community clinic setting. JGastroenterol Hepatol 2008, 23:1410-1414.
89. Czaja A.J., Beaver S.J., Shiels M.T. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987, 92:215-219.
90. Czaja A.J. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther 2014, 39:1043-1058.
91. Czaja A.J., Ammon H.V., Summerskill W.H. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980, 78:518-523.
92. Hegarty J.E., Nouri Aria K.T., Portmann B., et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983, 3:685-689.
93. Verma S., Gunuwan B., Mendler M., et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004, 99:1510-1516.
94. Czaja A.J., Ludwig J., Baggenstoss A.H., et al. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. NEngl J Med 1981, 304:5-9.
95. Johnson P.J., McFarlane I.G., Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. NEngl J Med 1995, 333:958-963.
96. Czaja A.J. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990, 11:1044-1049.
97. Czaja A.J., Carpenter H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. JClin Gastroenterol 2005, 39:819-825.
98. Czaja A.J. Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol 2013, 27:531-539.
99. Czaja A.J. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012, 26:615-620.
100. Czaja A.J. Management of recalcitrant autoimmune hepatitis. Curr Hepat Rep 2013, 12:66-77.